ClinicalTrials.gg
CompletedNCT04805307Updated Feb 12, 2025

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

A Phase 1 interventional study of CMG901 in Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma) and Pancreatic Cancer, sponsored by Keymed Biosciences Co.Ltd. Completed at 32 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
176
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 360 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Enrollment
112th of 508
176 · median 58
Started
2020
with 37 others
Phase 1
111 of 630
62 open now
Registered
206th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 112th largest by enrollment of the 508 interventional ones that give a count, is one of 38 that started in 2020, is one of 111 in phase 1, and was the 206th registered.

Pancreatic Neoplasms

3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.

The dose escalation phase (Part A) will determine the MTD of CMG901 in subjects with relapsed and/or refractory advanced solid tumor for which there is no available standard therapy likely to confer clinical benefit, or the subject is not a candidate for such available therapy based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design).

The dose expansion phase (Part B) will be conducted in subjects with advanced solid cancer with failure of standard treatment or no standard treatment who are Claudin 18.2 positive to preliminarily explore the efficacy and to determine the RP2D of CMG901.

03

Conditions studied

  • Advanced Solid Tumor
  • Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects with or cytologically confirmed advanced solid tumors, who have failed to respond to standard of care (progression after treatment or intolerance) or who have no available standard of care regimen.
  • Part A: Must provide specimen or agree to undergo a fresh biopsy if archival specimen is unavailable for retrospective Claudin 18.2 testing prior to enrollment;Subjects enrolled in Part A are not required to be positive for Claudin 18.2.
  • Part A: Measurable or evaluable lesions per v 1.1.Part B: At least one per RECIST v1.1.
  • Part B: Subjects shall provide fresh or archival tumor tissue samples before enrollment for assessment of Claudin 18.2 expression level (central laboratory) and should be positive for Claudin 18.2 as determined by the central laboratory. If the subject can provide positive Claudin 18.2 expression results which had been reported by the same central laboratory using the same method, there is no need for another test.
  • Women of and male subjects must agree to remain abstinent or use methods as defined by the protocol.
  • Performance Status 0-1.
  • Side effects of any prior therapy or procedures for any medical condition has recovered to v.5.0 Grade ≤ 1 or stable status by investigator.

Key Exclusion Criteria:

  • Received: chemotherapy or any anti-tumor agents within 28 days of the start of CMG901 treatment; molecularly-targeted agents, immunoconjugate, or antibody drug conjugate within 28 days or or 5 half-lives (whichever is shorter) of the start of CMG901 treatment; major surgery within 28 days of the start of CMG901 treatment; radiotherapy within 21 days of the start of CMG901 treatment; potent cytochrome P450 3A4 () inhibitors within 14 days or or 5 half-lives (whichever is longer) of the start of CMG901 treatment.
  • Diagnosis of immunodeficiency or requiring another form of chronic therapy. Or is receiving chronic systemic therapy (in doses exceeding 10 mg daily of prednisone or equivalent) within 7 days prior to the first dose.
  • History of severe to any component or of CMG901.
  • Ongoing or active infection or interstitial pneumonia assessed by investigator.
  • Any severe cardiac dysfunction including \<50%, congestive heart failure ≥Grade 2 (), >480 msec, major cardiovascular and cerebrovascular diseases (e.g., congestive cardiac failure, acute myocardial infarction, unstable angina, stroke, , deep vein thrombosis or pulmonary embolism) within 6 months prior to the first dose of study drug.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Subjects with uncontrolled ascites, pleural effusion, or pericardial effusion by investigator.
  • Preexisting sensory and/or motor neuropathy Grade ≥2.
  • Uncontrolled diabetes mellitus or diabetic neuropathy within 3 months of the first dose of CMG901.
  • Subjects with active or C, i.e., positive for anti- antibody and positive for HCV RNA, or positive for HBsAg with detectable positive for HBV DNA (i.e., ≥ 2000 IU/mL).
  • Any other conditions such as medical history, treatment, laboratory abnormalities that may confound the study results, interfere with the subject's compliance, or impair the interests of the subject, as assessed by the Investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Part A, Dose escalation

    CMG901 will be administered in treatment cycles once every 3 weeks (Q3W). Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.3mg/kg and 0.6mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (1.2mg/kg, 1.8mg/kg, 2.2mg/kg, 2.6mg/kg and 3.0mg/kg).

    Drug: CMG901

  • Experimental
    Part B, Dose expansion,2.2mg/kg

    This cohort will comprise subjects with Claudin 18.2 positive gastric cancer (including gastroesophageal junction adenocarcinoma), pancreatic cancer, and other solid cancer with prior failure of, progression on, or intolerance to, standard therapy.

    Drug: CMG901

  • Experimental
    art B, Dose expansion,3.0mg/kg

    This cohort will comprise subjects with Claudin 18.2 positive gastric cancer (including gastroesophageal junction adenocarcinoma), pancreatic cancer, and other solid cancer with prior failure of, progression on, or intolerance to, standard therapy.

    Drug: CMG901

  • Experimental
    Part B, Dose expansion,3.0mg/kg

    This cohort will comprise subjects with Claudin 18.2 positive gastric cancer (including gastroesophageal junction adenocarcinoma), pancreatic cancer, and other solid cancer with prior failure of, progression on, or intolerance to, standard therapy.

    Drug: CMG901

Interventions

  • DrugCMG901

    CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until confirmed Progressive Disease(PD), unacceptable toxicity, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of adverse events.Abnormal laboratory parameters, vital signs, 12-lead electrocardiogram and physical examination. Occurrence of Dose-limiting toxicity

    Time frame: Up to 30 days post the last dose, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first. DLTs are up to 21 days after the first dose

  2. Part A: To determine the maximum tolerated dose (MTD) of CMG901

    Time frame: Up to 21 days after the first dose

  3. Part B: To preliminarily evaluate the Objective Response Rate (ORR) per RECIST v1.1 of CMG901 in subjects with Claudin 18.2-positive advanced solid cancer

    Time frame: Up to 24 months

  4. Part B: Recommended phase II dose

    Time frame: Up to 24 months

Secondary outcomes

  1. Part A & Part B: Area Under the Curve from 0 to the time of the last measurable concentration [AUC(0-last)]

    Time frame: 21 days after the first dose

  2. Part A & Part B: Area Under the Curve over a dosing interval [AUC(0-tau)]

    Time frame: 21 days after the first dose

  3. Part A & Part B: Area Under the Curve from 0 to infinity [AUC(0-inf)]

    Time frame: 21 days after the first dose

  4. Part A & Part B: Peak Plasma Concentration (Cmax)

    Time frame: 21 days after the first dose

  5. Part A & Part B: Time of Maximum Observed Concentration (Tmax)

    Time frame: 21 days after the first dose

  6. Part A & Part B: Terminal elimination half-life (t1/2)

    Time frame: 21 days after the first dose

  7. Part A & Part B: Clearance (CL)

    Time frame: 21 days after the first dose

  8. Part A & Part B: Volume of distribution (Vz)

    Time frame: 21 days after the first dose

  9. Part A & Part B: Observed concentration at the end of a dosing interval(Ctrough)

    Time frame: 21 days after the first dose

  10. Part A & Part B: Area Under the Curve from 0 to the time of the last measurable concentration [AUC(0-last)]

    Time frame: up to 24 months

  11. Part A & Part B: Area Under the Curve over a dosing interval [AUC(0-tau)]

    Time frame: up to 24 months

  12. Part A & Part B: Peak Plasma Concentration (Cmax)

    Time frame: up to 24 months

  13. Time of maximum observed concentration (Tmax)

    Time frame: up to 24 months

  14. Part A & Part B: Terminal elimination half-life (t1/2)

    Time frame: up to 24 months

  15. Part A & Part B: Clearance (CL)

    Time frame: up to 24 months

  16. Part A & Part B: Volume of distribution (Vz)

    Time frame: up to 24 months

  17. Part A & Part B: Volume of distribution at steady-state (Vss)

    Time frame: up to 24 months

  18. Part A & Part B: Minimum concentration (Cmin)

    Time frame: up to 24 months

  19. Part A & Part B: Observed concentration at the end of a dosing interval (Ctrough)

    Time frame: up to 24 months

  20. Part A & Part B: Accumulation ratios of peak plasma concentration (Cmax) for multiple doses

    Time frame: up to 24 months

  21. Part A & Part B: Accumulation ratios of area under the curve over a dosing interval [AUC(0-tau)] for multiple doses

    Time frame: up to 24 months

  22. Part A & Part B: Incidence of anti-CMG901

    Time frame: up to 24 months

  23. Part A & Part B: Disease Control Rate (DCR) per RECIST v1.1

    Time frame: up to 24 months

  24. Part A & Part B: Duration of Response (DoR) per RECIST v1.1

    Time frame: up to 24 months

  25. Part A & Part B: Progression Free Survival (PFS) per RECIST v1.1

    Time frame: up to 24 months

  26. Part A&B:To evaluate the correlation between clinical efficacy of CMG901 and Claudin 18.2 expression

    Time frame: up to 24 months

  27. Part A: Objective Response Rate (ORR) per RECIST v1.1

    Time frame: up to 24 months

  28. Part A & Part B: Overall Survival (OS)

    Time frame: up to 24 months

  29. Part B: Incidence of adverse events graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Abnormal laboratory parameters, vital signs, 12-lead electrocardiogram and physical examination

    Time frame: Up to 30 days post the last dose, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first

07

Study locations

32 sites
  • Sun Yat-sen University Cancer Center (SYSUCC)
    Guangzhou, Guangdong, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Affiliated Hospital of Hebei University
    Baoding, China
  • Hunan Cancer Hospital
    Changsha, China
  • Sichuan Cancer Hospital
    Chengdu, China
  • Chongqing University Cancer Hospital
    Chongqing, China
  • Fujian Cancer Hosppital
    Fuzhou, China
  • Fujian Medical University Union Hospital
    Fuzhou, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
  • Hainan General Hospital
    Haikou, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, China
  • Harbin Medical University Cancer Hospital
    Harbin, China
  • The Second Hospital of Anhui Medical University
    Hefei, China
  • Affiliated Hospital of Jining Medical University
    Jining, China
  • Lanzhou University Second Hospital
    Lanzhou, China
  • The First Affiliated Hospital of Henan University of science and Technology
    Luoyang, China
  • Meizhou People's Hospital
    Meizhou, China
  • Jiangxi Cancer Hospital
    Nanchang, China
  • Huashan Hospital, Fudan University
    Shanghai, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, China
  • The First Hospital of China Medical University
    Shenyang, China
  • The Forth Hospital of Hebei Medical University and Hebei Tumor Hospital
    Shijiazhuang, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, China
  • Hubei Cancer Hospital
    Wuhan, China
  • Tongji Hospital Tongji Medical College of HUST
    Wuhan, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Apr 2024, 39 months.

Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 39 months is below that.

Counting every sponsor, half of 379 studies reached it within 45 months; a quarter within 32 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Mar 18, 2021
StartActual
Dec 24, 2020
Primary completionActual
Apr 5, 2024
CompletionActual
Apr 5, 2024
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04805307
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Dec 24, 2020
Primary completion
Apr 5, 2024
Completion
Apr 5, 2024
Last update
Feb 12, 2025

Study contacts

Ruihua Xu
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonesitatug vedotin

Start the discussion